**SUPPLEMENTS**

**Prediction of radio-resistant prostate cancer based on differentially expressed proteins**

Tim Nestler1, Maike Wittersheim2, Stephan Schaefer2, Martin Hellmich3, David Pfister1, Margarete Odenthal2, Melanie von Brandenstein1, Reinhard Buettner2, Axel Heidenreich1

1Department of Urology, University Hospital of Cologne, Cologne, Germany

2Institute of Pathology, University Hospital of Cologne, Cologne, Germany

3Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany

**Corresponding author:**

Tim Nestler, M.D.

Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery University Hospital Cologne

Kerpener Straße 62

50937 Cologne, Germany

Telephone: +49 221 478 82108

Fax: +49 221 478 82372

E-mail: tim.nestler@uk-koeln.de

ORCID-ID: 0000‐0001‐6033‐6364

**Supplementary** Figure 1: Visualization of the study hypothesis. The grey rectangle displays the radio-recurrent patients treated by SRP, the blue circle patients treated by PRP separated by Gleason high- and low-risk groups. The red area indicates the overlap of proteins being expressed of radio-recurrent patients and those with a high-risk Gleason score.

****